IP Library Granted Patent US 8,097,707
Granted Patent B2
US 8,097,707 · App. 12/851,359 · Granted Jan 17, 2012

Compositions and processes for preparing 13-deoxy-anthracyclines

Assignee: Gem Pharmaceuticals, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,097,707
App. No.
12/851,359
Granted
Jan 17, 2012
Kind
B2
Abstract

13-benzenesulfonylhydrazone anthracyclines useful in producing improved yields in the synthesis 13-deoxyanthracyclines, and an improved method of reducing 13-benzene-sulfonylhydrazone anthracyclines to 13-deoxyanthracyclines wherein the reduction reaction is maintained at temperatures of about 55° C. to 64° C. without stirring or agitation. The reaction is completed with the addition of aqueous bicarbonate which forms the 13-deoxyanthracycline and precipitates. The precipitates are filtered and the precipitate and filtrate are extracted separately with organic solvents. The crude 13-deoxy anthracycline can be converted to 5-imino-13-deoxy anthracycline by reaction with methanolic ammonia. The reaction can also be performed with an acidic pyridinium salt instead of a strong acid so that neutralization of the reaction or extraction of the product is not necessary, thereby facilitating purification.

Claims (34)

1. A method for producing a compound represented by the formula:

wherein:

R 1 , R 2 and R 3 are H or OH;

R 4 is H, OH, alkyl, or O-alkyl;

R 5 is O or NH; and

R 6 is a sugar moiety,

which comprises reacting a 13-keto anthracycline or acid salt thereof with benzene-sulfonylhydrazide in an alcohol solvent at about 35 to 50° C. for about 10 to 24 hours.

2. The method of claim 1 , wherein said compound is a derivative of an anthracycline selected from the group consisting of doxorubicin, daunorubicin, epirubicin, idarubicin, annamycin, and caminomycin.

3. A process for preparing 5-imino-13-deoxy anthracyclines comprising:

1) preparing a 13-deoxy anthracycline by

a) forming an alcohol solution of a 13-benzenesulfonylhydrazone anthracycline;

b) adding a reducing agent and an acid to said solution;

c) heating said solution, without agitation or stirring, to reduce said 13-benzene-, sulfonylhydrazone anthracycline; and

d) neutralizing said solution with aqueous base, thereby forming said 13-deoxy anthracycline and precipitates;

2) dissolving said 13-deoxy anthracycline in an alcohol; and

3) converting said 13-deoxy anthracycline to the corresponding 5-imino-13-deoxy anthracycline with ammonia at less than about 20° C.

4. The process according to claim 3 wherein the step of converting said 13-deoxy anthracycline to the corresponding 5-imino-13-deoxy anthracycline with ammonia is at about 1° C. to about 4° C. for 1 to 4 days.

5. The process according to claim 3 wherein said 13-deoxy anthracycline is selected from the group consisting of the 13-deoxy forms of doxorubicin, daunorubicin, epirubicin, idarubicin, annamycin and caminomycin.

6. A process for preparing 13-deoxy anthracyclines, comprising: 1) forming an alcohol solution of a 13-benzene-, or substituted benzene-, sulfonylhydrazone anthracycline; 2) adding a reducing agent and an acidic pyridinium salt to said solution; and 3) heating said solution to reduce said 13-benzene-, or substituted benzene-, sulfonylhydrazone anthracycline.

7. The process according to claim 6 , further comprising the step of hydrolyzing said reduced 13-benzene-, or substituted benzene-, sulfonylhydrazone anthracycline, thereby forming said 13-deoxy anthracycline.

8. The process according to claim 6 wherein said heating is at about 65° C. to about 75° C.

9. The process according to claim 6 wherein said 13-benzene-, or substituted benzene-, sulfonylhydrazone anthracycline is a derivative of an anthracycline selected from the group consisting of doxorubicin, daunorubicin, epirubicin, idarubicin, annamycin, and caminomycin.

10. A process for preparing 5-imino-13-deoxy anthracyclines comprising: 1) preparing a 13-deoxy anthracycline according to claim 6 ; and 2) converting said 13-deoxy anthracycline to the corresponding 5-imino-13-deoxy anthracycline with ammonia at less than about 20° C.

11. The process according to claim 10 wherein the step of converting said 13-deoxy anthracycline to the corresponding 5-imino-13-deoxy anthracycline with ammonia is at about 1° C. to about 4° C. for 1 to 4 days.

12. The process according to claim 10 wherein said 13-deoxy anthracycline is selected from the group consisting of the 13-deoxy forms of doxorubicin, daunorubicin, epirubicin, idarubicin, annamycin and caminomycin.

13. The process according to claim 10 wherein said 13-deoxy anthracycline is synthesized from a corresponding 13-benzenesulfonylhydrazone anthracycline.

14. A compound represented by the formula:

wherein:

R 1 , R 2 , and R 3 , are H or OH;

R 4 is H, OH, alkyl, or O-alkyl;

R 5 is O or NH; and

R 6 is H, OH, or a sugar moiety

produced by reacting a 13-keto anthracycline or acid salt thereof with benzene-sulfonylhydrazide in an alcohol solvent at about 35 to 50° C. for about 10 to 24 hours.

15. The compound of claim 14 , wherein said compound is a derivative of an anthracycline selected from the group consisting of doxorubicin, daunorubicin, epirubicin, idarubicin, annamycin, and caminomycin.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2017
From: GEM PHARMACEUTICALS, LLC
To: TACTICGEM, LLC
Reel/Frame 044100/0957 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2017
From: TACTICGEM, LLC
To: MONOPAR THERAPEUTICS INC.
Reel/Frame 044100/0977 →
Continuity (3)
Continuation 11777057 · Jul 12, 2007
Continuation 10982873 · Nov 8, 2004
Related Publication 20110028702A1 · Feb 3, 2011